The South African Tuberculosis Vaccine Initiative (SATVI) is a tuberculosis research group with a research focus that spans several disciplines including paediatrics, infectious diseases, epidemiology, public health, immunology, systems biology and clinical sciences. SATVI has a large and well-developed clinical field site in the Boland Overberg region, with the core on the premises of the Brewelskloof TB Hospital in Worcester, from where most clinical/epidemiological studies and clinical trials of new TB vaccines are conducted. The Immunology and Laboratory based work is led by Associate Professor Tom Scriba; and the Clinical Trials work is led by SATVI Director, Associate Professor Mark Hatherill.